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Abstract
Introduction: Both clinical experience and experimental evidence have suggested that Adrenocorticotropic
hormone (ACTH) might directly exert immunomodulatory effects not dependent on adrenal steroidogenesis.
Methods: The direct effects of H.P. Acthar Gel® (Acthar), a repository preparation containing a porcine ACTH analogue,
on human B lymphocyte function were studied in vitro using peripheral blood B cells isolated using anti-CD19 coated
magnetic beads and activated by interleukin 4 (IL-4) and CD40 ligand (CD40L). Analysis of expression of messenger
RNA (mRNA) encoding activation-induced cytidine deaminase (AICDA) was carried out by quantitative real-time
polymerase chain reaction (PCR). Cellular proliferation was assessed by a flow cytometric technique using intracellular
staining with carboxyfluorescein succinimidyl ester (CFSE). Immunoglobulin G (IgG) production was measured in cell
supernatants using an immunoassay.
Results: Acthar was found to exert acute, dose-dependent inhibitory effects on IL-4/CD40L–mediated induction of the
expression of activation-induced cytidine deaminase (AICDA) after 24 hours, as well as sustained inhibition of B cell
proliferation and IgG production during five more days of culture, without deleterious effects on B cell viability.
Conclusions: These experiments demonstrate that Acthar can exert direct effects on the humoral immune system
independent of any role in the regulation of adrenal steroidogenesis. Although the impact of these findings on clinical
disease was not evaluated in this study, these data support the therapeutic potential of Acthar for the management of
autoimmune diseases characterized by B cell activation and aberrant humoral immune function.
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Introduction
Adrenocorticotropic hormone (ACTH), also known as
corticotropin, is a member of a group of peptide hor-
mones (the melanocortins) derived from the proopiome-
lanocortin (POMC) gene by cell-specific transcription
patterns and post-translational processing [1]. The prin-
cipal source of these gene products is the pituitary and
central nervous system, although POMC gene expres-
sion occurs at lower levels in a variety of tissues [2]. The
melanocortins exert their physiologic effects via binding
to one or more of the members of a family of specific G-
protein coupled melanocortin receptors (MCRs) and ac-
tivation of the Jak/STAT pathway [3, 4].
While ACTH exerts its principal physiologic effect to
stimulate adrenal growth and to acutely regulate gluco-
corticoid production by the cells of the adrenal cortex
[1], extra-adrenal targets of ACTH action were postu-
lated over 50 years ago [5] and the recognition that
MCRs are expressed on a wide variety of cell types, in-
cluding cells of the immune system, has stimulated
renewed interest in the immunomodulatory properties
of these peptides [6]. Radioligand binding studies on
separated populations of rat lymphoid cells demon-
strated the highest levels of specific ACTH binding on B
lymphocytes, while T lymphocytes exhibited about half
that receptor capacity and thymocytes had low or un-
detectable levels of ACTH surface binding [7]. At the
mRNA level, quantitative PCR experiments have shown
lower levels of MCR gene expression in human periph-
eral B cells compared with CD4+ T cells, but mRNAs for
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MCR1, MCR3, and MCR5 (all of which bind ACTH)
have been identified in the CD19+ cell population [8].
ACTH may exert effects on physiologic processes either
directly (via MCR-mediated action on target cells) or in-
directly, through stimulation of adrenal steroidogenesis.
Early studies by both Hench et al. [9] and Thorn and
Bayles [10] compared the effects of ACTH with those of
glucocorticoids on the clinical features of human auto-
immune diseases such as rheumatoid arthritis. Both
groups concluded that an intact adrenal corticosteroid
biosynthetic response was essential for ACTH to mimic
the clinical effect of exogenous glucocorticoid therapy
[10, 11]. Until it became technically possible to examine hor-
mone action in isolated cells in culture, it was believed that
ACTH effects on immune system function could only be in-
directly exerted by stimulation of endogenous glucocorticoid
production by the adrenals. The first of such studies in vitro
reported inhibitory activity of ACTH on peripheral B-
lymphocyte function [12]. In that study, ACTH preparations
from porcine pituitary glands were found to suppress anti-
body production by murine spleen cells in vitro in re-
sponse to both T-cell-dependent and T-cell-independent
antigens that had been used as immunogens in vivo. The
observed suppressive effects of ACTH occurred at hor-
mone concentrations estimated to be in the micromolar
range [12]. Subsequent studies suggested contradictory ef-
fects of ACTH on human tonsillar B cells activated in
vitro by interleukin (IL)-2 or IL-4, reporting enhanced cel-
lular proliferation and antibody production [13, 14]. Pro-
inflammatory activities in T cells and natural killer cells
have also been described [15, 16]. Other investigators have
reported suppressive effects of synthetic ACTH on im-
munoglobulin E production in vitro by cultures of human
peripheral blood mononuclear cells but such effects were
not observed in highly purified B-cell populations [17].
We tested the effects of H.P. Acthar Gel® (Acthar, Mal-
linckrodt Pharmaceuticals, Ellicott City, MD, USA), a por-
cine pituitary-derived ACTH analog approved for the
treatment of certain autoimmune disorders in which B-cell
dysfunction may contribute to disease pathogenesis. Por-
cine ACTH differs from human ACTH at a single amino
acid (position 31) [18] but no differences have been identi-
fied in the steroidogenic, melanotrophic, or lipolytic activ-
ities of the ACTH peptides from these two species [19].
We examined the effects of this clinically utilized prepar-
ation on human B-lymphocyte function in vitro, using
highly purified B-cell populations cultured in the absence
of glucocorticoids and stimulated by recombinant IL-4 and
CD40 ligand (CD40L) as specific B-cell activating signals.
Methods
Human subjects, B-lymphocyte preparation, and culture
Healthy volunteer subjects were recruited for the study
and gave informed consent to participate in the protocol
approved by the Penn State/Milton S. Hershey Medical
Center Institutional Review Board. The volunteers included
16 females and nine males, with overall mean (± standard
error of the mean (SEM)) age of 37 (±2) years; each experi-
ment was carried out with a unique individual donor.
Peripheral blood mononuclear cells were prepared by
density gradient centrifugation on Histopaque 1077 (MP
Biomedicals, Santa Ana, CA, USA), and peripheral B lym-
phocytes were then isolated using magnetic CD19
MicroBeads (Miltenyi Biotec, San Diego, CA, USA) and a
MidiMACS Separator (Miltenyi Biotec). B cells prepared
using this method were analyzed by flow cytometry after
staining with anti-CD20 antibodies and found to be >90 %
pure. Recovered B cells were resuspended in complete
medium (RPMI 1640 with no phenol red, supplemented
with 9 % charcoal-stripped fetal bovine serum, 1 %
GlutaMAX-1, and 100 I.U./ml penicillin/100 μg/ml strepto-
mycin). Stimulated cultures (using 10 ng/ml IL-4 and
2 μg/ml recombinant human CD40L from HEK293 cells;
both R&D Systems, Minneapolis, MN, USA) and control
cultures were plated at a density of 0.5 × 106 –1.0 × 106
cells/ml. Acthar or placebo (provided in blinded fashion;
Mallinckrodt Pharmaceuticals, St. Louis, MO, USA) was
added to cultures to test the effects of varying estimated
concentrations of the active compound. Test compounds
were freshly prepared in complete medium on the day of
the experiment, within 1 hour prior to addition to cell cul-
tures. Placebo was identical to Acthar, except that it did not
contain any active compound. Both the Acthar and the pla-
cebo preparations were identical to those used in both clin-
ical studies [20] and animal studies in vivo [21]. Cells were
incubated at 37 °C with 5 % CO2 for varying lengths of time
from overnight to 6 days. No additions were subsequently
made to cultures during the incubation period.
Assays for immunoglobulins in cell culture supernatants
Immunoglobulin G (IgG) and immunoglobulin M (IgM)
levels in cell culture supernatants were measured using
immunoglobulin heavy chain-specific (IgG) and intact
molecule-specific (IgM) microsphere agglutination assays
(Pierce Easy Titer; Thermo-Fisher, Rockford, IL, USA).
Quantitation of cellular proliferation in culture
To assess effects of test compounds on B-cell prolifera-
tion, cells were stained with carboxyfluorescein succini-
midyl ester (CFSE; CellTrace from Molecular Probes,
Eugene, OR, USA) using the manufacturer’s protocol
prior to culture and stimulation in vitro. After comple-
tion of the incubation period, cells were harvested,
washed, and analyzed by flow cytometry using a BD
FACS Canto II instrument (BD Biosciences, Franklin
Lakes, NJ, USA) in the Penn State Hershey Flow Cytom-
etry Core Facility. The distribution of peaks of fluores-
cence intensity was analyzed using FlowJo software
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(TreeStar, Ashland, OR, USA) to yield the parameters of
percentage of cells that divided, division index (the average
number of divisions of all cells), expansion index (the
fold-expansion of all cells), proliferation index (the average
number of divisions of a responding cell), and replication
index (the fold-expansion of responding cells).
Flow cytometric assessment of cell viability
Cultured B cells were assessed for viability using the
LIVE/DEAD Fixable Dead Cell Stain kit with green
fluorescent reactive dye (Molecular Probes). Cells were
harvested from culture plates at the end of various treat-
ments, pelleted by centrifugation at 300 × g for 10 mi-
nutes, washed, and resuspended in phosphate-buffered
saline (PBS). Cells were stained with green fluorescent
amine reactive dye reconstituted in dimethylsulfoxide
(DMSO; 1 μl per million cells), stored on ice in the dark
for 30 minutes, and then washed once with PBS. Cells
were analyzed for dye exclusion (live cells) or inclusion
(dead cells) by flow cytometry on a BD FACS Canto II in-
strument in the Penn State Hershey Flow Cytometry Core
Facility using the 488 nm excitation laser and 530 nm de-
tection band. Parallel samples were analyzed by visual
microscopic inspection for trypan blue dye exclusion.
RNA isolation and RT-PCR quantitation of activation-
induced cytidine deaminase
RNA was isolated from harvested cells using the RNeasy
Mini Kit (Qiagen, Germantown, MD, USA) according to
the manufacturer’s instructions. The RNA concentration
was quantitated using a Nanodrop 2000c spectropho-
tometer (Thermo Fisher Scientific - Nanodrop Products,
Wilmington, DE, USA) . Reverse transcription of RNA
was performed using the High Capacity RNA to cDNA
Kit (Applied Biosystems, Life Technologies Corporation,
Carlsbad, CA, USA).
Activation-induced cytidine deaminase (AICDA) mRNA
expression was quantitated using real-time PCR technique
with Taqman® reagents from Applied Biosystems (Gene
Expression Assay Hs 00221068), with GAPDH (Gene
Expression Assay Hs 03929097) as a control mRNA for
calculation of induction using the ΔΔCt method. Assays
were run on an Applied Biosystems Quant Studio 12 K
Flex real-time PCR system in the Penn State Hershey
Genome Sciences facility.
Statistical analyses
Statistical analyses were carried out using Prism software
(version 6.0; Graph Pad, San Diego, CA, USA) or SAS
(SAS Institute Inc., Cary, NC, USA) Results are pre-
sented as mean and SEM values. Multiple measurements
were analyzed for statistical significance using analysis of
variance (ANOVA) with Tukey’s multiple comparison
post test or with the Kruskal–Wallis test with Dunn’s
multiple comparison post test for experiments in which
datasets were not normally distributed. p <0.05 was con-
sidered significant.
Results
Treatment of IL-4/CD40L-activated human B cells in vitro
with Acthar resulted in a dose-dependent reduction of
IgG accumulation in culture supernatants after 6 days
(Fig. 1, top panel). Maximal inhibition of IgG production
(72.7 %) was noted at an estimated ACTH analog concen-
tration of approximately 2.49 μM (p <0.01). Treatment
with placebo at identical volumes did not alter IgG levels
compared with IL-4/CD40L-stimulated controls. Effects
of the Acthar on IgM accumulation in culture superna-
tants were also observed—with maximal suppression of
70.8 % at the highest concentration of Acthar (p <0.05;
Fig. 1, bottom panel). Treatment with the placebo prepar-
ation did not result in significant effects on IgM.
During B-lymphocyte activation, the process of im-
munoglobulin class switching is known to be dependent
on cellular proliferation [22]. We therefore examined
whether Acthar altered IL-4/CD40L-induced prolifera-
tion of human B cells in vitro using CFSE staining to de-
fine successive waves of cellular proliferation in culture.
We noted a dose-dependent effect of Acthar to inhibit
proliferation of activated B cells—with significant reduc-
tions in the percentage of cells that divided in culture
(Fig. 2a), the average number of divisions of all cells
(Fig. 2b), and the fold-expansion of all cells (Fig. 2c).
Placebo treatment did not significantly alter any of
these parameters of cell proliferation. No significant differ-
ences were observed between unstimulated and IL-4/
CD40L-stimulated cells with respect to either the number
of divisions undertaken by responding cells (“proliferation
index”; not shown) or the fold-expansion of responding
cells (“replication index”; not shown).
The effects of Acthar on cell proliferation were not
explained by toxic or lytic effects on human B cells.
Neither intracellular staining with Live/Dead fluorescent
amine reactive dye (Fig. 3) or trypan blue exclusion (not
shown) revealed any significant effect of Acthar on these
assessments of cell integrity.
The ability of B cells to switch the class of immuno-
globulin produced from IgM to IgG is dependent not only
on cellular proliferation, but also on the action of the
DNA-modifying enzyme AICDA that initiates the gen-
omic changes resulting in immunoglobulin heavy chain
gene class switch recombination as well as somatic hyper-
mutation (SHM) of the variable regions of immunoglobu-
lin heavy and light chain genes [23, 24]. Examination of
AICDA expression in IL-4/CD40L-activated human B
cells revealed an acute, concentration-dependent inhibi-
tory action of the ACTH analog, reducing the levels of
AICDA ordinarily seen in the first 24 hours after such
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stimulation. At the highest concentration of Acthar,
AICDA expression was suppressed on average to 2.67 ±
0.92 % of IL-4/CD40L-stimulated values (p <0.05), com-
parable with the level of expression seen in unstimulated
cells (Fig. 4a). After 6 days in culture, AICDA mRNA
levels in Acthar-treated cells were comparable with those
observed in placebo-treated control cells, consistent with
the prediction that active peptide would not still be
present in cultures at this time point (Fig. 4b). Placebo-
treated cells did not show statistically significant changes
in AICDA expression at either time point. These data con-
firm that Acthar exerted an inhibitory effect on the expres-
sion of the key regulator of class switch recombination
and SHM in activated human B cells, and that this inhibi-
tory effect is exerted promptly during early phases of ex-
posure to the peptide.
Discussion
Acthar has US Food and Drug Administration approval
for treatment of a number of autoimmune conditions, in-
cluding the treatment of acute exacerbations of multiple
sclerosis, during an exacerbation or as maintenance ther-
apy in selected cases of systemic lupus erythematosus,
dermatomyositis, and polymyositis, and as adjunctive ther-
apy for short-term administration in psoriatic arthritis,
rheumatoid arthritis, and ankylosing spondylitis (Acthar
prescribing information). The therapeutic effects of ACTH
preparations in human autoimmune disorders have histor-
ically been believed to be the consequence of the stimula-
tory effect of the hormone on adrenal cortisol production
and secretion [10, 11, 25]. However, clinical observation of
therapeutic effects of Acthar in glucocorticoid-resistant pa-
tients with multiple sclerosis [26], prior in vitro observa-
tions of direct effects of ACTH preparations on cultured
human B cells [13], and the recognition that human
monocytes, macrophages, and T and B lymphocytes ex-
press specific MCRs [6, 8, 27] have all suggested that some
extra-adrenal effects of this corticotropin preparation
might be immunomodulatory. While we have found previ-
ously that glucocorticoids acutely downregulate AICDA
expression in cultured human B cells [28], the present re-
examination of the effects of Acthar on purified human B
lymphocytes supports direct effects of a clinically utilized
corticotropin preparation on the processes of B-cell activa-
tion and immunoglobulin G production, since our experi-
ments were performed in vitro under glucocorticoid-free
conditions.
The experiments presented here revealed an acute effect
of Acthar to suppress AICDA mRNA expression during
the first 24 hours of exposure to IL-4 and CD40L stimula-
tion. As we observed previously with glucocorticoid ex-
posure of human B cells, this effect on AICDA mRNA
expression was not sustained, but with Acthar we also
found significant suppression of cellular proliferation and
IgG production observable 5 days later, an effect not seen
with glucocorticoid treatment (glucocorticoid data not
shown). Since cellular proliferation is required for initi-
ation of IgG production in activated B cells [22], this effect
Fig 1 Immunoglobulin production by activated human B lymphocytes
in vitro is suppressed by Acthar. IgG (top panel) and IgM (bottom panel)
were measured in supernatants from human peripheral B cells cultured
for 6 days under basal conditions, with added IL-4/CD40L alone, or
with IL-4/CD40L plus added Acthar at ACTH analog concentrations of
approximately 0.124, 1.24, or 2.49 μM (stepped bars). Parallel cultures
contained IL-4/CD40L plus matched volumes of placebo. Supernatants
were harvested and assayed for IgG or IgM concentration and results
analyzed by ANOVA (Kruskal–Wallis test, p <0.0001 for IgG; p = 0.0551
for IgM). **Significantly different from IL-4/CD40L-stimulated samples
by Dunn’s post test at p <0.01. *Significantly different from IL-4/CD40L-
stimulated samples by Dunn’s post test at p <0.05. Results shown are
mean ± SEM for eight independent experiments. Acthar H.P. Acthar
Gel®, CD40L CD40 ligand, Ig immunoglobulin, IL interleukin
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could be interpreted as antiproliferative. The sustained ef-
fects of Acthar exposure on cellular proliferation and IgG
production, however mediated, do seem likely to depend
on early events, since it seems unlikely that active cortico-
tropin or related peptides remained in the cultures for any
sustained period of time. Whether our observations could
be the consequence of antagonism of IL-4 action, CD40L
Fig. 3 Viability of B lymphocytes in vitro is unaffected by Acthar. The
percentage of live cells (negative for staining) was assessed in human
peripheral B cells cultured for 6 days under basal conditions, with
added IL-4/CD40L alone, or with IL-4/CD40L plus added Acthar at
ACTH analog concentrations of approximately 0.124, 1.24, or 2.49 μM.
Parallel cultures contained IL-4/CD40L plus volumes of placebo at
equal volumes. At the end of the culture period cells were stained with
Live/Dead stain as described in Methods. Cells were analyzed by flow
cytometry. Statistical analysis (ANOVA) revealed none of the treatment
values to be significantly different from IL-4/CD40L-stimulated sample.
Results shown are mean ± SEM for six independent experiments. Acthar





Fig 2 Proliferation of activated human B lymphocytes in vitro is
suppressed by Acthar. a The percentage of cells that divided, b the
average number of divisions of all cells (division index), and c the
fold-expansion of all cells (expansion index) were assessed in CSFE-
loaded human peripheral B cells cultured for 6 days under basal
conditions, with added IL-4/CD40L alone, or with IL-4/CD40L plus
added Acthar at ACTH analog concentrations of approximately
0.124, 1.24, or 2.49 μM. Parallel cultures contained IL-4/CD40L plus
matched volumes of placebo. Cells were examined by flow cytometry
and data analyzed by ANOVA (Kruskal–Wallis test, p <0.0001 for
percentage of cells divided, p <0.0001 for division index, and p <0.0001
for expansion index). **Significantly different from IL-4/CD40L-stimulated
samples by Dunn’s post test at p <0.01. *Significantly different from
IL-4/CD40L-stimulated samples at p <0.05. Results shown are mean
± SEM for six independent experiments. Acthar H.P. Acthar Gel®,
CD40L CD40 ligand, IL interleukin
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action, or other processes operative in B-cell activation re-
mains to be explored.
Recently published studies have identified suppressive
effects of Acthar on humoral autoimmunity in the NZB/
W F1 mouse model of lupus [21]. The in vivo treatment
paradigm utilized in that study included glucocorticoid-
treated control animals, but did not explicitly address
the question of extra-adrenal versus adrenal-dependent
actions of the hormonal preparation (all animal subjects
had intact adrenals), so that corticotropin-stimulated
production of dehydroepiandrosterone (DHEA) or other
potentially immunomodulatory adrenal steroid products
could not be formally excluded. The direct effects of
Acthar observed on human B cells in vitro in the present
work support the contention that adrenal-independent
actions directed at B cells themselves were operative in
vivo. The in vivo treatment of NZB/W F1 mice with
Acthar was associated with expanded populations of im-
mature cells in transitional type 1 and marginal zone B
cells in the spleen, reductions in germinal center cells,
and reductions in circulating IgG and IgM autoantibody
titers [21]. The present studies in human cells in vitro
corroborate this finding of inhibitory effects of Acthar
on immunoglobulin production by circulating B cells
that have passed tolerance checkpoints.
Other melanocortin peptides have previously been
found to modulate immune function in models of in-
flammatory bowel disease [29, 30] and in models of T-
cell-mediated diseases including autoimmune uveitis [31,
32] and experimental autoimmune encephalomyelitis
[33]. Recent studies of melanocortin peptide effects on
murine models of systemic lupus erythematosus [21, 34]
have now also revealed potential therapeutic roles for
these peptides in B-cell-mediated autoimmunity. Our
current studies in human cells, cultured in vitro under
glucocorticoid-free conditions, suggest that direct effects
of one or more components of the Acthar preparation
on B lymphocytes may contribute to the disease modula-
tion observed in such models in vivo.
While clearly independent of ACTH effects on gluco-
corticoid biosynthesis, the molecular mechanisms under-
lying the observed effects of Acthar on B-lymphocyte
function remain to be explored. B lymphocytes have
been reported to express MCRs that could mediate these
hormonal effects. Human B cells have been found to ex-
press MCR1 and MCR3 mRNA [27] and a mouse pro-B
A B
Fig. 4 Expression of AICDA mRNA in activated human B lymphocytes in vitro is suppressed by Acthar. Expression of AICDA mRNA was assessed
in human peripheral B cells cultured a for 1 day or b for 6 days under basal conditions, with added IL-4/CD40L alone, or with IL-4/CD40L plus
added Acthar at ACTH analog concentrations of approximately 0.124, 1.24, or 2.49 μM. Parallel cultures contained IL-4/CD40L plus placebo at
matched volumes. mRNA was isolated and quantitated by RT/PCR as described in Methods. Data were analyzed by ANOVA (p = 0.0002 on day 1
and p = 0.9973 on day 6). *Significantly different from IL-4/CD40L-stimulated samples by Tukey’s post test at p <0.05; **Significantly different from
IL-4/CD40L-stimulated samples by Tukey’s post test at p <0.01. Results shown are mean ± SEM of six independent experiments at 1 day and of
seven independent experiments at 6 days. Acthar H.P. Acthar Gel®, AICDA activation-induced cytidine deaminase, CD40L CD40 ligand,
IL interleukin
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cell line has been reported to express MCR5 [4]. Intact
corticotropin (as well as alpha MSH, which corresponds
to the first 13 amino acids of ACTH) binds to these re-
ceptors [6, 27]. Our present studies have not identified
the molecular target or the receptor-signaling pathway
by which the observed effects on B cells are exerted.
Although it is difficult to directly extrapolate clinically
effective dose ranges from in vitro studies, these findings
of direct Acthar effects on the function of activated hu-
man B lymphocytes have implications for the treatment
of autoimmune diseases characterized by B-cell activa-
tion and humoral autoimmunity. Abnormalities of the
hypothalamic–pituitary–adrenal axis are associated with
many autoimmune disorders, and glucocorticoid resist-
ance of immune tissues in many of these patients has
been also described [35–37]. The observed direct effects
of Acthar on cellular targets in the humoral immune
system might thus be exploitable as an additional thera-
peutic approach.
Conclusions
These experiments are the first to demonstrate that a
clinically utilized ACTH preparation (H.P. Acthar® gel)
exerts direct immunomodulatory effects on human B
cells activated in vitro. The findings suggest potential for
such agents in the treatment of autoimmune diseases
characterized by abnormal B-cell activation.
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